Tenaya Therapeutics Inc Dossier - Source-backed chat

Tenaya Therapeutics Inc

TNYANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.19

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.60Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $135.3M

Enterprise Value $57.3M

Shares Outstanding 233.7M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tenaya Therapeutics is a high-conviction, clinical-stage biotechnology company uniquely positioned to address the underlying genetic drivers of heart disease. The company's investment thesis is anchored by highly encouraging clinical data from its two lead gene therapy programs: TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Recent clinical readouts in mid-2026 have demonstrated robust, durable reductions in disease hallmarks (such as cardiac hypertrophy and arrhythmia burden) with acceptable safety profiles. Backed by a strategic multi-target research collaboration with Alnylam Pharmaceuticals that extends its cash runway into the second half of 2027, Tenaya is entering a catalyst-rich period focused on securing regulatory alignment for pivotal registrational pathways.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$3.20

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

Regulatory agencies require larger, longer-term Phase 3 trials instead of accelerated pathways, delaying commercialization. Unforeseen safety signals emerge in higher-dose cohorts or during long-term follow-up, or the company faces dilutive financing pressure as the cash runway nears its end in 2027.

Base CaseCentral scenario

$4.0050%

Tenaya successfully aligns with regulators on standard registrational pathways for TN-201 and TN-401 by late 2026 or early 2027. Clinical trials continue to show durable efficacy and manageable safety. The company successfully regains Nasdaq compliance and advances TN-301 into patient trials, maintaining its cash runway through mid-2027.

Bull CaseUpside scenario

$8.0030%

Rapid regulatory alignment with the FDA and EMA on accelerated approval pathways for both TN-201 and TN-401, utilizing surrogate biomarkers (such as LVMI reduction and PVC burden reduction). Successful initiation of pivotal trials, coupled with milestone payments from the Alnylam collaboration, significantly drives up valuation and attracts major biopharma M&A interest.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling clinical proof-of-concept data for TN-201 showing consistent cardiac remodeling (LVMI reduction) and symptom relief sustained up to two years.
Robust efficacy for TN-401 in ARVC patients, demonstrating deep and durable reductions in arrhythmia burden (mean PVC reductions of 60-67%) and electrical stability.
Strategic validation and non-dilutive funding from the Alnylam Pharmaceuticals collaboration, providing $10M upfront and up to $1.1B in potential milestones.
Strong regulatory tailwinds, including PRIME designation from the EMA for both TN-201 and TN-401, and FDA Rare Pediatric Disease and Orphan Drug designations.

Key Investment Risks

Clinical and regulatory risks associated with securing alignment on pivotal trial designs and accelerated approval pathways.
Financial risk and potential dilution as the current cash runway is projected to fund operations only into the second half of 2027.
Nasdaq minimum bid price non-compliance risk, requiring the stock to trade above $1.00 to avoid potential delisting or restructuring.
Manufacturing and scale-up complexities inherent to AAV9-based gene therapies.

Thesis Invalidation Triggers

Emergence of severe, unresolved safety or tolerability issues in the high-dose cohorts of TN-201 or TN-401.
FDA or EMA refusal to accept surrogate endpoints for registrational pathways, significantly extending the timeline to approval.
Failure to secure additional non-dilutive or dilutive financing before the cash runway falls below 12 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.